FISHERS, Ind., Jan. 27, 2012 /PRNewswire/ -- Positron
Corporation (OTCBB:POSC), a leading molecular imaging healthcare
company, specializing in the field of nuclear cardiology, is
pleased to announce that on January 23,
2012, its wholly owned subsidiary, Manhattan Isotope
Technology (MIT), received approval of
its radioactive materials license amendment. The Texas
Department of State Health Services- Radiation Control Program
granted the amendment approval.
This specific amendment will now permit for the receipt and
processing of solutions, which contain Sr-82 and multiple other
radioisotopes. Over the next six months MIT will obtain Sr-82 target solutions, from
foreign irradiators, for final purification into Active
Pharmaceutical Ingredient (API) grade Sr-82 at the MIT facility in Lubbock, TX.
During proton irradiation to produce Sr-82, many other
radioisotopes are co-produced. These additional isotopes are
removed from Sr-82 during radiochemical processing. The
previous MIT radioactive materials
license was limited to two radioisotopes: Sr-82 and Sr-85.
The new amended license broadens the scope of isotopes permitted on
site and allows MIT greater flexibility
in this validation phase.
Commenting on the significance of the license approval,
MIT President and Positron
Pharmaceutical, Chief Technical Officer, Jason Kitten stated, "Positron and MIT are rapidly implementing a new foundation for
cardiac PET by increasing the supply and reliability of
Sr-82. Positron has designed a superior integrated business
model for the reliability and expansion of cardiac PET in the US.
With this latest license approval, MIT
has significantly accelerated Positron's Sr-82 mission and will
begin supporting Sr-82 supply in 2012, further strengthening
Positrons goal of solidifying cardiac PET's progression in the
US."
About Positron: Positron Corporation is a leading molecular
imaging healthcare company providing innovative nuclear medicine
technologies and solutions that are reshaping the field of nuclear
cardiology. Through proprietary PET imaging systems, services
and radiopharmaceutical solutions, Positron enables healthcare
providers to more accurately diagnose disease and improve patient
outcomes while practicing cost effective medicine. Positron
has gained significant traction in a diverse industry and continues
their strong commitment to excellence and advancing cardiac imaging
solutions. More information about Positron is available at
www.positron.com.
Forward Looking Statements: Statements in this document contain
certain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, as amended. These statements are based on
many assumptions and estimates and are not guarantees of future
performance. These statements may involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Positron Corporation to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Positron assumes no obligation to publicly update or
revise these forward-looking statements for any reason, or to
update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new
information becomes available in the future. Our actual
results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including,
without limitation those set forth as "Risk Factors" in our filings
with the Securities and Exchange Commission.
SOURCE Positron Corporation